Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8813MR)

This product GTTS-WQ8813MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ8813MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15618MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ12358MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ4164MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ10879MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ3542MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ14904MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ8777MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ1907MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGN 150998
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW